NJ A3852

Establishes the Psilocybin Behavioral Health Access and Therapy Pilot Program within the Department of Health to support hospital-based psilocybin research for treating behavioral health conditions including substance use disorders, depression, anxiety, and end-of-life psychological distress

Creates an 11-member Psychedelic Therapy and Research Advisory Board, including behavioral healthcare providers, clinical trial experts, and public health officials, to oversee the program and make recommendations for statewide psilocybin access

Selects three participating hospitals—one each from the northern, central, and southern regions of New Jersey—through a competitive application process within 240 days of the act's effective date

Appropriates $6 million from the General Fund, with $2 million allocated to each of the three selected hospitals to conduct FDA and DEA-compliant psilocybin research

Requires the department and advisory board to submit reports after year two of the pilot program with findings, outcomes data, and recommendations for potential statewide expansion of therapeutic psilocybin access